Mumbai: Glenmark Pharmaceuticals Ltd. (Glenmark), a research led, global pharmaceutical company, today announced its financial results for the second quarter ended September 30, 2026. Consolidated revenue for Q2 FY27 was Rs. 42,473 million. On a like-for-like basis, consolidated revenue grew approximately 20% YoY.
EBITDA for the quarter was Rs. 8,638 million, representing an EBITDA margin of 20.3%.
Adjusted Profit After Tax (PAT) for the quarter was Rs. 4,852 million, with an adjusted PAT margin of 11.4%. Reported Profit After Tax (PAT) was Rs. 2,638 million, with a reported PAT margin of 6.2%.
Commenting on the results, Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd. said, “Q2 demonstrated the strength and resilience of Glenmark’s base business. We remain on track to deliver our FY27 guidance with continued growth in India, a strong recovery in North America supported by multiple launches, and robust performance across Emerging Markets. RYALTRIS® continues to expand internationally with the recent Brazil launch marking an important milestone. Our partnered innovative oncology pipeline is advancing toward commercialization with the first launch expected by the end of FY27.
IGI continues to advance its multispecific oncology pipeline with Phase 1 ISB 2001 data selected for oral presentation at the 2026 American Society of Hematology (ASH) Annual Meeting. We also intend to submit an IND application for ISB 2301 by the end of this year. Together, these milestones underscore the strength of our innovation platform and position Glenmark for its next phase of sustainable, innovation-led growth, and long-term value creation,” he added.
****
